Dexmedetomidine
From Wikipedia, the free encyclopedia
 |
|
|
Dexmedetomidine
|
|
| Systematic (IUPAC) name | |
| 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole | |
| Identifiers | |
| CAS number | |
| ATC code | N05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C13H16N2 |
| Mol. mass | 200.28 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 94% |
| Metabolism | ? |
| Half life | 2 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Dexmedetomidine is a sedative medication used by intensive care units and anesthesiologists. It is relatively unique in its ability to provide sedation without causing respiratory depression. Like clonidine, its mechanism of action is agonism of alpha-2 receptors in certain parts of the brain. It has sedative, analgesic, sympatholytic, and anxiolytic effects that blunt many of cardiovascular responses in the perioperative period. By then, it reduces the volatile anesthetic, sedative and analgesic requirements without significant respiratory depression.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
